Table 2:
Immune checkpoint inhibitors
| Checkpoint | Checkpoint inhibitor | Malignancies with FDA approved use |
|---|---|---|
| CTLA-4 | Ipilimumab (Yervoy) | Melanoma (unresectable or metastatic); monotherapy, in combination with ipilimumab; adjuvant |
| Renal cell carcinoma (advanced or metastatic); combination with nivolumab | ||
| Microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer; monotherapy or in combination with nivolumab | ||
| Hepatocellular carcinoma (in combination with ipilimumab) | ||
| PD-1 | Nivolumab (Opdivo) | Melanoma (unresectable or metastatic), monotherapy pr in combination with ipilimumab; adjuvant |
| Squamous NSCLC (metastatic) | ||
| Renal cell carcinoma (advanced) | ||
| Classical Hodgkin’s lymphoma (relapsed) | ||
| Head and neck squamous cell carcinoma (recurrent or metastatic) | ||
| Urothelial carcinoma (advanced or metastatic) | ||
| Microsatellite instability-high or mismatch repair deficient metastatic CRC; monotherapy or in combination with ipilimumab | ||
| Hepatocellular carcinoma (monotherapy or in combination with ipilimumab) | ||
| Renal cell carcinoma (advanced or metastatic); monotherapy or in combination with ipilimumab | ||
| Pembrolizumab (Keytruda) | Melanoma (unresectable or metastatic) | |
| NSCLC (metastatic) | ||
| Head or neck squamous cell carcinoma (recurrent or metastatic) | ||
| Classical Hodgkin’s lymphoma (refractory) | ||
| Urothelial carcinoma (locally advanced or metastatic) | ||
| Microsatellite instability-high or mismatch repair deficient solid tumors and colorectal cancer | ||
| Gastric or gastroesophageal junction adenocarcinoma (locally advanced or metastatic) | ||
| Cervical cancer (recurrent or metastatic) | ||
| Primary mediastinal large B cell lymphoma (refractory) | ||
| Hepatocellular carcinoma | ||
| Merkel cell carcinoma (recurrent or metastatic) | ||
| Cutaneous squamous cell carcinoma (advanced) | ||
| Cemiplimab (Libtayo) | Cutaneous squamous cell carcinoma (advanced) | |
| PD-L1 | Atezolizumab (Tecentriq) | Urothelial carcinoma (locally advanced or metastatic) |
| NSCLC (metastatic) | ||
| Small cell lung cancer (metastatic) | ||
| Avelumab (Bavencio) | Merkel cell carcinoma (metastatic) | |
| Urothelial carcinoma (locally advanced or metastatic) | ||
| Advanced renal cell carcinoma | ||
| Durvalumab (Imfinzi) | Urothelial carcinoma (locally advanced or metastatic) Unresectable stage III non-small cell lung cancer |
|
| NSCLC (unresectable) | ||
| Select examples of emerging ICI in clinical trials | ||
| LAG-3 (CD223) | BMS-986016 (Relatlimab) LAG525 (IMP701) REGN3767 TSR033 MK-4280 TSR-033 Sym022 |
Clinical studies pending for advanced hematologic and solid tumors, including NSCLC (metastatic), RCC (advanced), metastatic or unresectable melanoma, microsatellite high (MSI-H) and non-MSI-H colon cancer, gastro-esophageal cancer, glioblastoma, gliosarcoma, Hodgkin’s lymphoma, DLBCL |
| TIM-3 | BMS-986258 TSR-022 (Cobolimab) BGB-A425 MBG453 LY3415244 |
Clinical studies pending for advanced cancer |
| VISTA | CA-170 (oral PD-L1, PD-L2, VISTA checkpoint antagonist) JNJ-61610588 |
Clinical studies pending for advanced cancer |